Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial

In this randomized controlled trial of 286 participants with elevated triglycerides, treatment with vupanorsen, an ANGPTL3 inhibitor, lowered remnant cholesterol by up to 59% and VLDL cholesterol by up to 67% over placebo.The effect of the treatment was sustained throughout 24 weeks and consistent across key patient subgroups.ANGPTL3 inhibition may be a promising approach to treat patients with elevated triglycerides.